

Lung Cancer: What the Primary Care Physician Needs To Know

Jim Allen, MD

Professor Emeritus, Department of Internal Medicine The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education



Case history & physical exam

History:

- 46 year old banker
- 2 month history of nonproductive cough
- 15 pound weight loss
- Smoked 1 PPD for 30 years


Physical Exam:


- Decreased breath sounds over right lower lobe
- Dullness to percussion lower right lung





Lung Cancer Epidemiology


- 238,340 new cases per year
- 127,070 U.S. deaths annually
- Lifetime risk:
 - 1:15 men
 - 1:17 women
















There are racial differences in lung cancer diagnosis and survival




Age of diagnosis of lung cancer:





Risk Factors For Lung Cancer


Smoking


- Environmental tobacco smoke
- Genetics
- Radon
- Asbestos
- Radiation therapy
- Emphysema
- Pulmonary fibrosis











Common presenting symptoms of lung cancer:

- Cough
- Hemoptysis
- Chest pain
- Hoarseness
- Dyspnea
- Malaise/anorexia

Clubbing





Making A Tissue Diagnosis:

When Used How Used

Sputum cytology Rarely Large central lesions

Bronchoscopy Commonly Lesions > 2 cm

CT-guided needle biopsy Occasionally Peripheral lesions

Thoracentesis Occasionally Pleural effusion

Endobronchial ultrasound Occasionally Large lymph nodes

Mediastinoscopy Occasionally Large lymph nodes


Thoracotomy/VATS Commonly Other tests indeterminate

21

Bronchoscopy







Diagnostic Utility:


If endobronchial lesion visible: 94%

If peripheral nodule > 2 cm: 40-50%

If peripheral nodule < 2 cm: 10%

Image Courtesy of the National Library of Medicine

Case Bronchoscopic Findings



- Endobronchial tumor involving RML and RLL
- Biopsy = large cell undifferentiated lung cancer

23


Staging System For Lung Cancer


- T = <u>Tumor</u>
 - 0-4; subcategorized as "a", "b", & "c"
 - based on size & location
- N = Nodes
 - 0-3
 - based on location of involved lymph nodes
- M = <u>Metastases</u>
 - 0-1; subcategorized as "a", "b", & "c"
 - Based on presence or absence of metastases


TNM Score Determines Stage

T/M	N0	N1	N2	N3
T1a	IA1	IIB	IIIA	IIIB
T1b	IA2	IIB	IIIA	IIIB
T1c	IA3	IIB	IIIA	IIIB
T2a	IB	IIB	IIIA	IIIB
T2b	IIA	IIB	IIIA	IIIB
T3	IIB	IIIA	IIIB	IIIC
T4	IIIA	IIIA	IIIB	IIIC
M1a/b	IVA	IVA	IVA	IVA
M1c	IVB	IVB	IVB	IVB

But... There's an app for that







Staging approach for non-small cell lung cancer


- History & physical examination
- Labs: CBC, chemistry profile, calcium, liver enzymes
- Chest CT
- PET scan (in clinical stage IB, IIA, and IIB)
- Other imaging studies if metastases suspected
- Bronchoscopy with EBUS or mediastinoscopy if lymph nodes are large
- Biopsy abnormal sites if it will affect management

Chest CT

- Advantages:
 - Excellent determination of calcification patterns
 - Provides guide to bronchoscopy & mediastinoscopy


- Disadvantages:
 - Large number of false positive adrenal masses (approximately 2/3 of adrenal masses will be benign)
 - Large number of false positive lymph nodes

Case CT



31

PET-CT Scans In Lung Cancer Staging





Disadvantages:


- Poor for "T" staging
- Poor for brain metastases
- False positives common


Advantages:

- Improved detection of mediastinal involvement
- Improved detection of distant metastases









Endobronchial Ultrasound (EBUS)





37

Mediastinoscopy






Image Courtesy of the National Library of Medicine

Non-Small Cell Lung Cancer Treatment

Stage la Surgery

Stage Ib Surgery (with *possible* adjuvant chemotherapy, immunotherapy, and/or osimertinib*)

Stage II Surgery + adjuvant chemotherapy, immunotherapy, and/or osimertinib*

Stage III Chemotherapy ± radiation therapy followed by immunotherapy

Possible late surgery

Stage IV Chemotherapy ± Immunotherapy or driver-directed treatment

*Adjuvant chemotherapy = cisplatin + second drug Immunotherapy if PD-L1 ≥ 1% Osimertinib if tumor is EGFR positive

Pre-op evaluation*

- PFTs: FEV1 & DLCO > 80% desirable
- If FEV1 and/or DLCO are < 80%
 - The predicted post-operative FEV1 and DLCO should be calculated, typically using quantitative ventilation/perfusions scans
 - A low tech exercise test (ability to walk up 5 flights of stairs) or high tech exercise test (cardiopulmonary exercise test) should be performed.
- ABG: PCO2 < 45 desirable (?)

*Never Miss An Opportunity To Refer A Surgically Curable Patient For Surgery!

Cardiopulmonary Exercise Testing For The Patient With A Marginal FEV1:

- mVO2 > 20 ml/kg/min
 - Surgery
- mVO2 < 10 ml/kg/min:
 - Surgery is too high risk
- mVO2 10-20 ml/kg/min:
 - Possible surgery
 - Consider pulmonary rehabilitation first

Case Outcome:

- Stage IIB
- Pre-op FEV1 = 2.74 liters (70% of predicted)
- Predicted post-op FEV1 = 50% of predicted
- Able to easily walk up 5 flights of stairs
- ABG: PCO2 = 40 (normal)

- Underwent right middle and lower lobe resection
- Cancer free 30 years later

Small Cell Lung Cancer

Limited Stage:

- 30% of patients
- Average survival = 17 months
- Treatment:
 - Stage I: surgery plus chemotherapy
 - Stage II & III: radiation plus chemotherapy
 - Prophylactic cranial radiation recommended
- Cure rate = 20%

Extensive Stage:

- 70% of patients
- Average survival = 12 months
- Treatment: chemotherapy
 ± immunotherapy
- Cure rate = 1 2%

Small cell lung cancer is essentially never curable by surgery alone!!!

١.,

Staging approach to small cell lung cancer*

- Chest CT
- Abdominal CT
- Pelvic CT
- Lab tests
- Brain MRI (or head CT)
- PET scan

^{*}Staging should not delay starting chemotherapy and is mainly to determine whether radiation should be given (limited stage)

Inoperable ≠ Untreatable

Medical Treatment of Advanced Non-Small Cell Lung Cancer in 2025

- Driver mutations can guide treatment:
 - EGFR (+) --- EGFR tyrosine kinase inhibitors such as osimertinib
 - ALK (+) --- ALK tyrosine kinase inhibitors such as alectinib
 - BRAF (+) BRAF/MEK inhibitors such as dabrafenib and trametinib
 - ROS1 (+) ROS1 inhibitor <u>crizotinib</u>
 - Others: MET, RET, NTRK, KRAS

Medical Treatment of Advanced Non-Small Cell Lung Cancer in 2025 (continued)

- If PD-L1 (programmed death receptor-ligand 1) high (> 50%), immunotherapy with possible chemotherapy*:
 - <u>Pembrolizumab</u> monoclonal antibody against programmed death receptor-1 (PD-1); aka checkpoint inhibitor
- If PD-L1 low (< 50%) or negative, immunotherapy with chemotherapy:
 - Chemotherapy* + pembrolizumab)

*Chemotherapy is typically a platinum drug plus a second drug


In 10 years, the preferred treatments for advanced nonsmall cell lung cancer will have changed... a lot

Tomorrow's Patients Will Owe Their Lives To Today's Patients In Clinical Trials


Palliation of Lung Cancer

- External beam radiation
- Brachytherapy
- Cryotherapy
- Argon plasma coagulation
- Stents
- Photodynamic therapy
- Laser
- Pleurodesis

68 Year Old Man With Tracheal Squamous Cell Carcinoma








Trachea Post-Stent

51

Argon Plasma Coagulation









CC BY-NC 4.0: Wang Y, Li Y, Wang F, et al. J Inter Med Res 2021 49(9):1-9


Cryotherapy


- Bronchoscopic probe placement
- · Nitrous oxide
- Probe tip = -40° C



53

Screening Chest CT Scans For Lung Cancer





N = 53,454

N Engl J Med 2011. 365:395-409

Results of screening chest CTs:

- Lung cancers found in earlier stages
- Overall, 20% reduction in mortality
- High false positive rate:
 - Overall 30% of CT scans were abnormal
 - A suspicious abnormality was 27 times more likely to be benign than malignant
- Screening CTs plus follow-up CTs are very expensive

Medicare Lung Cancer Screening Requirements:


- Age 50-80
- Asymptomatic
- More than 20 pack-year smoking history
- Current smoker or quit in the past 15 years
- Counseling session that includes risks/benefits of screening and includes smoking cessation counseling


*Continue screening annually until > 15 years since guit smoking

What do you do about the incidentally identified solitary pulmonary nodule?

Indicators of benign pulmonary nodules

- Calcification patterns
- Age
- Smoking history
- Size
- History of cancer
- Radiographically stable over time






Clinical Approach To The Solitary Pulmonary Nodule "Benign" calcification pattern? Yes No No further work-up Yes Unchanged on x-ray for 2 years? No Risk of malignancy? Low High Serial Surgical Intermediate chest resection PET scan or CT scans Abnormal Bronchoscopy or Normal CT-guided needle











The average smoker loses 14 minutes of life for every cigarette smoked



























90% of smokers begin before age 18

10.1% of high school students and 5.4% of middle school students use tobacco products



30-Day Prevalence of Daily Use of Cigarettes and Nicotine Vapes 1990 - 2022



CC BY-NC 4.0: Pierce JP, Luo M, McMenamin SB, et al. Tob Control Epub ahead of print: [11/8/2023]. doi:10.1136/tc-2022-057907



Key Points About Lung Cancer

- Extremely high mortality rate
- Caused by cigarettes
- Screening chest CTs now recommended
- Stage dictates treatment and prognosis
 - Small cell extensive/non-extensive
 - Non-small cell TNM system

